Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Cash & Equivalents

Cash & Equivalents at other companies

Baxter International logo
Baxter InternationalBAX
$2.02B-12.1%
PTH
Pelthos Therapeutics Inc.PTHS
$31.98M+24,250%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$24.47M-46.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
RFL
Rafael Holdings, Inc.RFL
$30.5M-19.6%
Organon logo
OrganonOGN
$1.12B+104%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's cash & equivalents?
Cumberland Pharmaceuticals (CPIX) reported cash & equivalents of $11.01M in Q1 2026.
How has Cumberland Pharmaceuticals's cash & equivalents changed year-over-year?
Cumberland Pharmaceuticals's cash & equivalents decreased by 27.1% year-over-year, from $15.11M to $11.01M.
What is the long-term trend for Cumberland Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Cumberland Pharmaceuticals's cash & equivalents has grown at a -14.3% compound annual growth rate (CAGR), from $24.75M to $11.44M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.